STRASBOURG, France--(BUSINESS WIRE)--Odimma Therapeutics, a biotechnology company specialized in personalized cancer immunotherapy announces a seed fundraising of €2 million in order to secure the preparation on its First-in-Man clinical trial with ODI-2001, an innovative first-in-class personalized immunotherapy against cancer.
Touchlight and Odimma Therapeutics have entered an agreement for the development and supply of clinical material for usage in the latter’s neoantigen programme for cancer.
Touchlight and Odimma Therapeutics Announce Clinical Material Supply Agreement to Develop Personalised Cancer Therapy Utilising Doggybone DNA